LRRK2 and nervous system disorder: This cohort included 9 wild-type controls (8 healthy subjects and 1 corrected wild-type), 30 PD patients bearing mutations in SNCA, LRRK2, or GBA without the presence of signs for other neurological disorders, 42 asymptomatic genetic carriers (named “Risk”), and 6 individuals exhibiting prodromal symptoms such as hyposmia or RBD but without PD diagnosis (named “Risk-Hyposmia” and “Risk-RBD,” respectively; Supplementary Table 1).